Addendum to the Editorial “Joint Guidance on Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors”

Abstract

TO THE READERSHIP: The purpose of the editorial in the May issue (1) was to bring to the attention of the readership a guidance document written collaboratively by 3 organizations, including the Society of Nuclear Medicine and Molecular Imaging (2). The decision to publish this document in the European Journal of Nuclear Medicine and Molecular Imaging was made collaboratively by the 3 organizations, as was the decision to publish the editorial in The Journal of Nuclear Medicine. Incidentally, we described clinical trials with these agents that are getting under way in the United States. We overlooked mentioning the availability of 2 ongoing Food and Drug Administration–authorized investigational new drug (IND) trials on high-activity 111 In-octreotide (IND no. 72,037) (3,4 )a nd 177 Lu-octreotate (IND no. 78,256) peptide receptor radionuclide therapies in the United States. These ongoing trials are available at the Excel Diagnostics and Nuclear Oncology Center in Houston, Texas.